Healthcare / Drug Manufacturers - Specialty & GenericBSE
$31.98
-0.08 (-0.25%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 34% · confianza 18%
FCF escenarios
weak_data · normalized FCF $-9.7M · quality 44.3/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
59/100
C
Piotroski
3/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$535M
P/E
5.9x
↓EV/EBITDA
3.5x
↓ROE
16.9%
↑Gross Margin
26.3%
↓Debt/Equity
0.02
↓TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
+19.0%
FCF CAGR
—
FCF margin
5.6%
FCF / Net income
0.39x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $506.6M · net income $72.4M · FCF $28.3M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $506.6M | $506.6M | $400.2M | $361.5M | $300.6M |
| Net Income | $72.4M | $72.4M | $62.0M | $52.1M | $18.4M |
| EBITDA | $99.5M | $99.5M | $87.4M | $71.5M | $27.4M |
| EPS | 6.26 | 6.26 | 5.36 | 4.49 | 1.59 |
| Gross Margin | 26.3% | 26.3% | 26.7% | 26.3% | 14.0% |
| Operating Margin | 19.9% | 19.9% | 22.1% | 22.7% | 9.6% |
| Net Margin | 14.3% | 14.3% | 15.5% | 14.4% | 6.1% |
| Balance Sheet | |||||
| Debt/Equity | 0.02 | 0.02 | 0.02 | 0.12 | 0.01 |
| Current Ratio | 7.96 | 7.96 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $28.3M | $28.3M | $-28.1M | $-9.7M | $-877000.00 |
| Returns | |||||
| ROE | 16.9% | 16.9% | 17.3% | 35.8% | 20.6% |
| Valuation | |||||
| P/E | 5.91 | 5.91 | 11.03 | — | — |
| EV/EBITDA | 3.48 | 3.48 | 7.31 | — | — |
| P/B | 0.87 | 0.87 | 1.91 | — | — |
| Growth & Yield | |||||
| Revenue Growth | 26.6% | 26.6% | 10.7% | 20.3% | — |
| EPS Growth | 16.8% | 16.8% | 19.4% | 182.6% | — |
| Dividend Yield | 1.1% | 1.1% | — | — | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
3Y implied EPS CAGR
-23.2%
EPS terminal req.
$2.84
Spread vs growth
40.0%
5Y implied EPS CAGR
-11.3%
EPS terminal req.
$3.43
Spread vs growth
28.1%
10Y implied EPS CAGR
-1.2%
EPS terminal req.
$5.53
Spread vs growth
18.0%
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
-14.7%
Start / end P/E
7.1x → 5.1x
EPS bridge
5.36 → 6.26
Residual
-4.7%
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.